Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Tegaserod is effective in the initial and retreatment of irritable bowel syndrome with constipation
Author: Muller-Lissner, S.
Holtmann, G.
Rueegg, P.
Weidingers, G.
Lofflers, H.
Citation: Alimentary Pharmacology and Therapeutics, 2005; 21(1):11-20
Publisher: Blackwell Publishing Ltd
Issue Date: 2005
ISSN: 0269-2813
Statement of
S. Műller-Lissner, G. Holtmann, P. Rueegg, G. Weidinger & H. Lőffler
Abstract: <jats:title>Summary</jats:title><jats:p><jats:bold>Background</jats:bold> : Symptoms of irritable bowel syndrome are often cyclical and thus may require repeated rather than continuous therapy. Tegaserod is effective and well‐tolerated for irritable bowel syndrome with constipation but data on retreatment are lacking.</jats:p><jats:p><jats:bold>Aim</jats:bold> : To assess whether tegaserod retreatment is as efficacious and well‐tolerated as initial treatment in a primary care setting.</jats:p><jats:p><jats:bold>Methods</jats:bold> : This open‐label trial was designed to evaluate the effectiveness of tegaserod under real‐life conditions. Irritable bowel syndrome with constipation patients received tegaserod 6 mg b.d. for 12 weeks; response was assessed at weeks 4 and 12. Responders (those achieving satisfactory relief for at least 2 of the previous 4 weeks) at weeks 4 and/or 12 entered an 8‐week withdrawal period where symptom recurrence was assessed. Patients experiencing recurrence could receive tegaserod 6 mg b.d. for another 4 weeks (retreatment phase) and on completion, could choose to continue tegaserod in a 6‐month extension study.</jats:p><jats:p><jats:bold>Results</jats:bold> : A total of 513 patients received initial treatment with tegaserod; 85.0% (436 of 513) responded. 403 responders entered the withdrawal period; symptoms recurred in 83.9% (338 of 403) after a mean of 38 days. Of the 307 patients who subsequently entered retreatment 89.3% (274 of 307) responded. Among patients entering the retreatment period, 269 (87.6%) had responded within the first 4 weeks of initial treatment. Of these, 243 (90.3%) responded to tegaserod retreatment. Adverse events were infrequent and similar during 4 weeks of the initial treatment period (11.1%) and on retreatment (10.4%). The extension study, completed by 188 of 232 (81.0%) patients, demonstrated good long‐term tolerability of tegaserod.</jats:p><jats:p><jats:bold>Conclusions</jats:bold> : Irritable bowel syndrome with constipation patients can be successfully treated, and retreated, with tegaserod 6 mg b.d. Tegaserod was well‐tolerated during initial and retreatment periods.</jats:p>
Description: © 2005 Blackwell Publishing Ltd.
DOI: 10.1111/j.1365-2036.2004.02294.x
Published version:
Appears in Collections:Aurora harvest 5
Medical Sciences publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.